Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Blackledge

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
British Journal of Obstetrics and Gynaecology|April 1, 1986
Random urinary cyclic 3',5' guanosine monophosphate in epithelial ovarian cancer: relation to other prognostic variables and to survivalD M Luesley, G R Blackledge, K K Chan, et al.
American Journal of Clinical Oncology|January 1, 1988
Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research GroupL A Emtage, C Trethowan, C Hilton, et al.
British Journal of Obstetrics and Gynaecology|May 1, 1987
Serial urinary cyclic guanosine monophosphate measurements in the assessment of response to treatment in epithelial ovarian cancerD M Luesley, K K Chan, J R Newton, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1990
Haemostatic changes during hormone manipulation in advanced prostate cancer: a comparison of DES 3 mg/day and goserelin 3.6 mg/monthL A Emtage, J George, B J Boughton, et al.
British Journal of Cancer|March 1, 1994
A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancerS Kehoe, C J Poole, A Stanley, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 1989
Survival after negative second-look laparotomyD M Luesley, K K Chan, F G Lawton, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancerN S Stuart, M H Cullen, T J Priestman, et al.
British Journal of Cancer|December 1, 1993
Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancerC J Williams, V L Barley, G R Blackledge, et al.
Clinical Endocrinology|April 1, 1985
A radioimmunoassay for GnRH agonist analogue in serum of patients with prostate cancer treated with D-Ser (tBu)6 AZA Gly10 GnRHR N Clayton, L C Bailey, J Cottam, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Early serum CA125 response and outcome in epithelial ovarian cancerC W Redman, G R Blackledge, K Kelly, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
British Journal of Obstetrics and Gynaecology|April 1, 1986
Random urinary cyclic 3',5' guanosine monophosphate in epithelial ovarian cancer: relation to other prognostic variables and to survivalD M Luesley, G R Blackledge, K K Chan, et al.
American Journal of Clinical Oncology|January 1, 1988
Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research GroupL A Emtage, C Trethowan, C Hilton, et al.
British Journal of Obstetrics and Gynaecology|May 1, 1987
Serial urinary cyclic guanosine monophosphate measurements in the assessment of response to treatment in epithelial ovarian cancerD M Luesley, K K Chan, J R Newton, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1990
Haemostatic changes during hormone manipulation in advanced prostate cancer: a comparison of DES 3 mg/day and goserelin 3.6 mg/monthL A Emtage, J George, B J Boughton, et al.
British Journal of Cancer|March 1, 1994
A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancerS Kehoe, C J Poole, A Stanley, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 1989
Survival after negative second-look laparotomyD M Luesley, K K Chan, F G Lawton, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancerN S Stuart, M H Cullen, T J Priestman, et al.
British Journal of Cancer|December 1, 1993
Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancerC J Williams, V L Barley, G R Blackledge, et al.
Clinical Endocrinology|April 1, 1985
A radioimmunoassay for GnRH agonist analogue in serum of patients with prostate cancer treated with D-Ser (tBu)6 AZA Gly10 GnRHR N Clayton, L C Bailey, J Cottam, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Early serum CA125 response and outcome in epithelial ovarian cancerC W Redman, G R Blackledge, K Kelly, et al.
Pageof 5